Single-ascending Dose Study of Kylo-11 in Healthy Subjects

Inclusion Criteria:

• Men and women aged 18 to 55 years old, inclusive;

• Body mass index (BMI) between 19 kg/m2 and 30 kg/m2, inclusive;

• Protocol-defined elevated serum Lp(a) level;

• Female subjects must not be able to get pregnant and male subjects must agree toadhere to contraception restrictions;

• Willing to comply with protocol required visits and assessments, and provide writteninformed consent.

Exclusion Criteria:

• History or evidence of a clinically significant disorder, condition or disease;

• Received an investigational drug, vaccine or device within 3 months before dosing;

• History of evidence of malignant tumor or Gilbert syndrome;

• Positive screen of Hepatitis B surface antigen, hepatitis C virus, humanimmunodeficiency virus or syphilis infection;

• History of alcohol abuse within 12 months before dosing;

• History of drug abuse within 3 months before screening;

• History of blood donations or blood loss of 400 ml and more within 3 months beforedosing;

• History of stroke or myocardial infarction within 6 months before sceening;

• Pregnant or breast-feeding women;

• Other exclusion criteria applied per protocol.